C-type natriuretic peptide protects the retinal pigment epithelium against advanced glycation end product-induced barrier dysfunction

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 1, 2013, Pages 96-102

  Dahrouj, Mohammad ^a   Alsarraf, Oday ^a   Liu, Yueying ^a   Crosson, Craig E ^a   Ablonczy, Zsolt ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; GLYCOSYLATED ALBUMIN; NATRIURETIC PEPTIDE TYPE C;

ARPE 19 CELL LINE; ARTICLE; BLOOD RETINA BARRIER; CELL LINE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ELECTRIC RESISTANCE; FETUS; HUMAN; HUMAN CELL; HUMAN TISSUE; PHARMACOLOGICAL BLOCKING; PIGMENT EPITHELIUM; PRIORITY JOURNAL; TRANSEPITHELIAL ELECTRICAL RESISTANCE;

ATRIAL NATRIURETIC FACTOR; BLOOD-RETINAL BARRIER; BLOTTING, WESTERN; CELL LINE; CYCLIC AMP; CYCLIC GMP; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; RETINAL PIGMENT EPITHELIUM; SERUM ALBUMIN; SIGNAL TRANSDUCTION;

EID: 84871706938     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.199307     Document Type: Article

References (32)

1. Ablonczy Z and Crosson CE (2007) VEGF modulation of retinal pigment epithelium resistance. Exp Eye Res 85:762-771. (Pubitemid 350166363)
2. Ablonczy Z, Dahrouj M, Tang PH, Liu Y, Sambamurti K, Marmorstein AD, and Crosson CE (2011) Human retinal pigment epithelium cells as functional models for the RPE in vivo. Invest Ophthalmol Vis Sci 52:8614-8620.
3. Ablonczy Z, Prakasam A, Fant J, Fauq A, Crosson C, and Sambamurti K (2009) Pigment epithelium-derived factor maintains retinal pigment epithelium function by inhibiting vascular endothelial growth factor-R2 signaling through gammasecretase. J Biol Chem 284:30177-30186.
4. Ahmed N (2005) Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract 67:3-21.
5. Aiello LM (2003) Perspectives on diabetic retinopathy. Am J Ophthalmol 136: 122-135.
6. Baetz NW, Stamer WD, and Yool AJ (2012) Stimulation of aquaporin-mediated fluid transport by cyclic GMP in human retinal pigment epithelium in vitro. Invest Ophthalmol Vis Sci 53:2127-2132.
7. Cohen MP, Hud E, Wu VY, and Shearman CW (2008) Amelioration of diabetesassociated abnormalities in the vitreous fluid by an inhibitor of albumin glycation. Invest Ophthalmol Vis Sci 49:5089-5093.
8. Dunn KC, Aotaki-Keen AE, Putkey FR, and Hjelmeland LM (1996) ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 62:155-169. (Pubitemid 26140102)
9. Fritz G (2011) RAGE: a single receptor fits multiple ligands. Trends Biochem Sci 36: 625-632.
10. Fujiseki Y, Omori K, Omori K, Mikami Y, Suzukawa J, Okugawa G, Uyama M, and Inagaki C (1999) Natriuretic peptide receptors, NPR-A and NPR-B, in cultured rabbit retinal pigment epithelium cells. Jpn J Pharmacol 79:359-368. (Pubitemid 29168147)
11. Horiuchi S, Sakamoto Y, and Sakai M (2003) Scavenger receptors for oxidized and glycated proteins. Amino Acids 25:283-292. (Pubitemid 38041266)
12. Kakehashi A, Inoda S, Mameuda C, Kuroki M, Jono T, Nagai R, Horiuchi S, Kawakami M, and Kanazawa Y (2008) Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy. Diabetes Res Clin Pract 79:438-445. (Pubitemid 351273462)
13. Katoli P, Sharif NA, Sule A, and Dimitrijevich SD (2010) NPR-B natriuretic peptide receptors in human corneal epithelium: mRNA, immunohistochemistochemical, protein, and biochemical pharmacology studies. Mol Vis 16 :1241-1252.
14. Lara-Castillo N, Zandi S, Nakao S, Ito Y, Noda K, She H, Ahmed M, Frimmel S, Ablonczy Z, and Hafezi-Moghadam A (2009) Atrial natriuretic peptide reduces vascular leakage and choroidal neovascularization. Am J Pathol 175:2343-2350.
15. Levin ER, Gardner DG, and Samson WK (1998) Natriuretic peptides. N Engl J Med 339:321-328. (Pubitemid 28366422)
16. Li YM, Mitsuhashi T, Wojciechowicz D, Shimizu N, Li J, Stitt A, He C, Banerjee D, and Vlassara H (1996) Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 93:11047-11052. (Pubitemid 26333115)
17. Mäepea O (1992) Pressures in the anterior ciliary arteries, choroidal veins and choriocapillaris. Exp Eye Res 54:731-736.
18. Marmor MF and Negi A (1986) Pharmacologic modification of subretinal fluid absorption in the rabbit eye. Arch Ophthalmol 104:1674-1677. (Pubitemid 17174536)
19. Peyroux J and Sternberg M (2006) Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes. Pathol Biol (Paris) 54:405-419. (Pubitemid 44468299)
20. Potter DE, Russell KR, and Manhiani M (2004) Bremazocine increases C-type natriuretic peptide levels in aqueous humor and enhances outflow facility. J Pharmacol Exp Ther 309:548-553. (Pubitemid 38542606)
21. Potter LR, Abbey-Hosch S, and Dickey DM (2006) Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 27:47-72. (Pubitemid 43228238)
22. Rollín R, Mediero A, Fernández-Cruz A, and Fernández-Durango R (2005) Downregulation of the atrial natriuretic peptide/natriuretic peptide receptor-C system in the early stages of diabetic retinopathy in the rat. Mol Vis 11: 216 -224.
23. Rollín R, Mediero A, Roldán-Pallarés M, Fernández-Cruz A, and Fernández-Durango R (2004) Natriuretic peptide system in the human retina. Mol Vis 10:15-22.
24. Tamura Y, Adachi H, Osuga J, Ohashi K, Yahagi N, Sekiya M, Okazaki H, Tomita S, Iizuka Y, Shimano H, et al. (2003) FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products. J Biol Chem 278:12613-12617. (Pubitemid 36800020)
25. Telegdy G, Adamik A, and Glover V (2000) The action of isatin (2,3-dioxoindole) an endogenous indole on brain natriuretic and C-type natriuretic peptide-induced facilitation of memory consolidation in passive-avoidance learning in rats. Brain Res Bull 53:367-370.
26. Warboys CM, Toh HB, and Fraser PA (2009) Role of NADPH oxidase in retinal microvascular permeability increase by RAGE activation. Invest Ophthalmol Vis Sci 50:1319-1328.
27. Wautier JL and Guillausseau PJ (2001) Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 27:535-542. (Pubitemid 33051702)
28. Wistow G, Bernstein SL, Wyatt MK, Fariss RN, Behal A, Touchman JW, Bouffard G, Smith D, and Peterson K (2002) Expressed sequence tag analysis of human RPE/ choroid for the NEIBank Project: over 6000 non-redundant transcripts, novel genes and splice variants. Mol Vis 8:205-220. (Pubitemid 36153610)
29. Xing J, Moldobaeva N, and Birukova AA (2011) Atrial natriuretic peptide protects against Staphylococcus aureus-induced lung injury and endothelial barrier dysfunction. J Appl Physiol 110:213-224.
30. Yamada Y, Ishibashi K, Ishibashi K, Bhutto IA, Tian J, Lutty GA, and Handa JT (2006) The expression of advanced glycation endproduct receptors in rpe cells associated with basal deposits in human maculas. Exp Eye Res 82:840-848. (Pubitemid 43170884)
31. Yamagishi S, Nakamura K, and Matsui T (2006) Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy. Curr Drug Discov Technol 3:83-88.
32. Yokoi M, Yamagishi SI, Takeuchi M, Ohgami K, Okamoto T, Saito W, Muramatsu M, Imaizumi T, and Ohno S (2005) Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br J Ophthalmol 89:673-675. (Pubitemid 40780571)